Minardi Simona, De Rosa Salvatore, Salvi Nicolò, Andò Giuseppe, Talanas Giuseppe, D'angelo Claudio, Moretti Carolina, Mazza Tiziano Maria, Cortese Bernardo, Musumeci Giuseppe, Rubboli Andrea, Sciahbasi Alessandro
Division of Cardiology, Sant'Eugenio Hospital, Rome, Italy.
Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.
J Geriatr Cardiol. 2025 Aug 28;22(8):701-708. doi: 10.26599/1671-5411.2025.08.002.
Antithrombotic strategies after percutaneous coronary interventions (PCI) in elderly patients on oral anticoagulant therapy (OAT) are debated due to the balance between ischemic and bleeding risks. Recent guidelines recommend early transitioning from triple antithrombotic therapy to dual antithrombotic therapy, but there are limited data on elderly patients.
We performed a age-specific analysis of the PERSEO Registry population aimed to compare clinical features, therapeutic strategies, and outcomes of individuals aged ≥ 80 years and < 80 years who were on OAT and underwent PCI with stent. The primary endpoint was net adverse clinical events at 1-year follow-up. Secondary endpoints included major adverse cardiac and cerebral events (MACCE), major bleeding [Bleeding Academic Research Consortium (BARC) type 3-5], and clinically relevant bleeding (BARC type 2-5).
Among the 1234 patients enrolled, 31% of patients were aged ≥ 80 years (84 ± 3 years, 76% males). Compared to younger patients, elderly patients had higher rates of comorbidities such as hypertension, anaemia or chronic kidney disease, and atrial fibrillation was the leading indication for OAT. Elderly patients were more often discharged on dual antithrombotic therapy (23%) compared to younger patients (13%) ( < 0.0001). They experienced higher net adverse clinical events (38% 21%, < 0.001), MACCE (24% 12%, < 0.001), as well as higher bleeding rates. Specifically, rates of major bleeding (9% 6%, = 0.026), and clinically relevant bleeding (21% 12%, < 0.001) were significantly higher in elderly patients.
Elderly patients on OAT undergoing PCI are a particular frail population with higher risk of MACCE and bleeding compared to younger patients despite a less aggressive antithrombotic therapy.
口服抗凝治疗(OAT)的老年患者经皮冠状动脉介入治疗(PCI)后的抗栓策略因缺血风险和出血风险之间的平衡而存在争议。近期指南推荐早期从三联抗栓治疗过渡到双联抗栓治疗,但老年患者的数据有限。
我们对PERSEO注册研究人群进行了年龄特异性分析,旨在比较接受OAT且接受支架植入PCI的≥80岁和<80岁个体的临床特征、治疗策略及结局。主要终点为1年随访时的净不良临床事件。次要终点包括主要不良心脑血管事件(MACCE)、大出血[出血学术研究联盟(BARC)3 - 5型]和临床相关出血(BARC 2 - 5型)。
在纳入的1234例患者中,31%的患者年龄≥80岁(84±3岁,76%为男性)。与年轻患者相比,老年患者合并症发生率更高,如高血压、贫血或慢性肾脏病,且房颤是OAT的主要适应证。与年轻患者(13%)相比,老年患者更常接受双联抗栓治疗出院(23%)(P<0.0001)。他们经历了更高的净不良临床事件(38%对21%,P<0.001)、MACCE(24%对12%,P<0.001),以及更高的出血率。具体而言,老年患者的大出血发生率(9%对6%,P = 0.026)和临床相关出血发生率(21%对12%,P<0.001)显著更高。
接受OAT且接受PCI的老年患者是一个特别脆弱的人群,尽管抗栓治疗不那么积极,但与年轻患者相比,发生MACCE和出血的风险更高。